10-Q: Precigen Reports Q2 2024 Results, Announces Strategic Shift to Focus on PRGN-2012

Precigen announced its Q2 2024 financial results and a strategic shift to prioritize the development of PRGN-2012, including a reduction in workforce and the shutdown of ActoBio operations.

Summary

• Precigen reported a net loss of $58.8 million for the three months ended June 30, 2024, and a net loss of $82.5 million for the six months ended June 30, 2024.
• The company's total revenue for the three months ended June 30, 2024, was $0.7 million, and $1.8 million for the six months ended June 30, 2024, primarily from its Exemplar segment.
• A strategic prioritization was announced in August 2024, focusing on the development of PRGN-2012 and resulting in a workforce reduction of over 20% and the shutdown of ActoBio operations.
• The company recorded non-cash impairment charges of $34.5 million related to the shutdown of ActoBio.
• Precigen is planning to submit a Biologics License Application (BLA) for PRGN-2012 under an accelerated approval pathway in the second half of 2024.
• The company's cash and cash equivalents and short-term investments totaled $19.5 million as of June 30, 2024.
• A public offering in August 2024 raised approximately $31.4 million in net proceeds.
• There is substantial doubt about the company's ability to continue as a going concern due to its current cash position and expected operating losses.

Sentiment

Score: 3

Explanation: The document presents a mix of positive developments (focus on PRGN-2012, BLA submission) and significant negative factors (substantial losses, going concern warning, workforce reduction, ActoBio shutdown). The overall sentiment is negative due to the financial challenges and restructuring.

Positives

• The FDA has agreed that the Phase 1/2 clinical trial of PRGN-2012 will serve as pivotal for the purpose of filing an accelerated approval request for licensure.
• PRGN-2012 has been granted Breakthrough Therapy Designation and Orphan Drug designation for the treatment of RRP by the FDA.
• The company successfully raised $31.4 million in a public offering in August 2024.
• The company is focusing resources on PRGN-2012, which has the potential for commercialization in 2025.

Negatives

• The company has incurred significant losses since its inception and expects to continue to incur losses.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company is shutting down ActoBio operations, resulting in significant impairment charges.
• The company has reduced its workforce by over 20%.
• Revenues from the Exemplar segment have decreased.
• The company has paused enrollment in the PRGN-2009 cervical cancer trial at non-NCI clinical sites.
• The company has paused the PRGN-3005 and PRGN-3007 UltraCAR-T clinical trials.

Risks

• The strategic prioritization and streamlining of resources may not achieve the intended outcome.
• The company may not be able to raise sufficient additional capital.
• The company's success is dependent on key individuals and intellectual property.
• The company faces competition from other products and companies.
• There are technical risks associated with the successful research, development, and clinical manufacturing of its product candidates.
• The company's ability to continue as a going concern is uncertain.

Future Outlook

The company plans to submit a BLA for PRGN-2012 under an accelerated approval pathway in the second half of 2024 and is preparing for a potential commercial launch in 2025. The company is also exploring potential non-dilutive financings for future liquidity.

Management Comments

• The company is strategically prioritizing its pipeline to focus on the development of PRGN-2012.
• The company is streamlining resources, including a reduction in workforce and the shutdown of ActoBio operations.
• The company is focused on pre-commercialization efforts for PRGN-2012, including supporting submission of a rolling BLA under an accelerated approval pathway.

Industry Context

The company's strategic shift reflects a broader trend in the biotech industry where companies are focusing on core assets and streamlining operations to extend cash runways. The focus on PRGN-2012 aligns with the growing interest in gene therapies for rare diseases.

Comparison to Industry Standards

• The company's revenue is significantly lower than many comparable biotech companies, reflecting its early-stage development focus.
• The company's cash burn rate is high, which is typical for companies in the clinical development phase, but the company's cash position is lower than many peers.
• The strategic shift to focus on PRGN-2012 is similar to other biotech companies that have streamlined their pipelines to focus on lead assets.
• The company's decision to shut down ActoBio is a significant move, which is not uncommon for companies that are facing financial challenges and need to reduce costs.
• The company's reliance on external funding is a common risk for biotech companies, but the company's going concern warning is a significant concern.

Legal Proceedings

• The company is involved in ongoing litigation, but does not believe that any such matters will have a material adverse effect on the company's business, financial condition, results of operations, or cash flows.
• The company has resolved a shareholder class action lawsuit with a settlement payment of $13 million.

Related Party Transactions

• In January 2023, related parties and their affiliates purchased 11,517,712 shares in a public offering.
• In August 2024, related parties and their affiliates purchased 23,588,234 shares in a public offering.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial challenges and going concern warning.
• Employees have been impacted by the workforce reduction of over 20%.
• Customers of Exemplar may be affected by the decrease in services performed.
• The company's strategic shift may impact the development of other programs and technologies.

Next Steps

• The company plans to submit a BLA for PRGN-2012 in the second half of 2024.
• The company will conduct a confirmatory clinical trial for PRGN-2012.
• The company will continue acceleration of commercial readiness efforts for a potential launch of PRGN-2012 in 2025.
• The company will continue PRGN-2009 Phase 2 clinical trials under a CRADA with the NCI.
• The company will minimize UltraCAR-T spend and focus on strategic partnerships.
• The company will assess potential next steps with respect to the future of the ActoBio programs and intellectual property.

Key Dates

Keywords

PRGN-2012, AdenoVerse, UltraCAR-T, RRP, Biopharmaceuticals, Exemplar, ActoBio, clinical trials, gene therapy, immunotherapy, financial results, strategic prioritization, workforce reduction, BLA, going concern